Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain ...

Merck (NYSE:MRK) said a Phase 3 study of its drug Keytruda in the treatment of a certain type of ovarian cancer met its primary endpoint of progression-free survival, but not its secondary ...

Keytruda plus chemo showed ... an overall survival benefit in ovarian cancer,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.

RAHWAY, N.J. – Merck & Co., Inc., a global healthcare ... particularly in treating challenging forms of ovarian cancer. Currently, KEYTRUDA is not approved for the treatment of ovarian cancer ...

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 therapy Keytruda (pembrolizumab) in ovarian cancer. The phase 3 KEYNOTE-B96 ...

KEYTRUDA ® (pembrolizumab) plus chemotherapy (paclitaxel) with or without bevacizumab is the first immune checkpoint inhibitor-based regimen to show a statistically significant improvement in OS ...

Keytruda is not approved to treat ovarian cancer. Lynparza (olaparib), which is being jointly developed and commercialized by AstraZeneca and Merck, has three approved ovarian cancer indications in ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

“This marks the first time a Keytruda-based ... overall survival benefit in ovarian cancer,” said Dr Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement ...

Currently, KEYTRUDA is not approved for the treatment of ovarian cancer, but it has multiple approved indications in the United States for other cancers, including melanoma, non-small cell lung cancer ...